Introduction
Pharmaceutical dosage forms are required to meet stringent standard of drug content uniformity and quality. This situation is to ensure that product consistently delivers the intended dose, thereby achieving the desired efficiency. However, formulation development is one of the most challenging aspects of pharmaceutical and biopharmaceutical innovations. It involves navigating the complexities of pharmaceutical sciences and manufacturing, while achieving regulatory compliance. The current methods of drug delivery aim to deploy medication intact to specifically targeted part of the body through a medium that can control the therapy administered by means of either a physiological or chemical trigger. To achieve these, drug delivery scientists are turning to the world of micro-and nanotechnology as particulate systems of drug delivery.
Lipid based drug delivery system such as liposomes, microemulsions, nanoemulsions, self emulsifying systems, solid lipid micro-and nanoparticle are becoming more popular because lipid materials are easily characterized and can be developed for several administration routes. The reasons for increasing interest in lipid based system include: reduced plasma profile variability, better characterization of lipidic recipient, formulation versatility, choice of different drug delivery systems and improved ability to address the key issue of technology transfer and manufacture scale up [1] .
The bioavailability of orally administered lipophilic drug is low. There are usually several factors for this reason, but a particular widespread problem is poor absorption due to slow or incomplete dissolution in gastrointestinal tract. Formulation strategies to enhance solubility will ultimately increase bioavailability. Solid lipid based drug Objective: To formulate and evaluate in vitro, surface-modified solid lipid microspheres containing halofantrine using lipid matrix formed from goat fat and a phospholipid (P90H). Methods: The model drug, halofantrine in an increasing concentration of 1%, 2%, 3%, 4% and 5% w/w was incorporated into surface-modified solid lipid microspheres formulated by hot homogenization. Effect of drug concentration on the encapsulation efficiency was studied. The dispersion was evaluated using particle size, particle morphology, pH and encapsulation efficiency. The drug formulation with highest encapsulation efficiency was selected and used for the release studies and compared with the release from a commercial dosage form (Halfan® 250 mg tablet, Glaxo-Smithkline, Mayenne France) using simulated gastric fluid (SGF pH 1.2), simulated intestinal fluid (SIF pH 7.2) and phosphate buffer (pH 6.8) as biorelevant media. Results were analyzed statistically and the level of significance was taken to be P<0.05). Results: Discrete and spherical solid lipid microspheres were produced. The particle size of the dispersion was low (32.48-33.87 毺 m) with minimal particle growth and high encapsulation efficiencies (86.8%-91.0%) after 3 months. The pH of the microspheres dispersion changed appreciably after 3 months. In vitro release result obtained revealed sustained and controlled drug release from the lipid microspheres compared with the tablet dosage form. Conclusions: Formulation of halofantrine as solid lipid microspheres presents a better alternative to the conventional tablet formulation as the in vitro dissolution of the highly lipophilic halofantrine was highly improved.
delivery systems have been shown to enhance dissolution and bioavailability of lipophilic drugs [2] . Halofantrine is phenanthrene methanol derivative antimalarial agent active against asexual form of Plasmodium falciparum [3] . It is practically insoluble in water but freely soluble in methanol and sparingly soluble in ethanol [4] . The aim of the present study was to formulate and evaluate in vitro surface-modified solid lipid microspheres drug delivery system of halofantrine. This novel method of formulation of this drug has not been reported previously. However, it is believed that bioavailability of halofantrine is increase in the presence of fats. It was worthwhile to formulate lipid microspheres containing halofantrine using biocompatible lipids and assess the properties of such dosage form in vitro. In different studies, halofantrine was formulated as lipid emulsion or microemulsion concentrate [5] [6] [7] [8] . Phospholipid employed in this study has several advantages in drug delivery. Advantages of phospholipids formulations not only comprise enhanced bioavailability of drugs with low aqueous solubility or low membrane penetration potential, but also improvement or alteration of uptake and release of drugs, protection of sensitive active agents from degradation in the gastrointestinal tract, reduction of gastrointestinal side effects of non-steroidal anti-inflammatory drugs and even masking of bitter taste of orally administered drugs [2] .
Materials and methods

Materials
These following materials were used as procured from their supplier's without further purification: methanol (M&B Dagenham, England), activated charcoal, sorbitol, polysorbate 80 (Merck, Darmstadt Germany), sodium hydroxide (BDH, Poole England), monobasic potassium phosphate, hydrochloric acid (Sigma, USA), disodium hydrogen phosphate, sodium dihydrogen phosphate (SigmaAldrich, Germany), Halfan® 250 mg tablets (GlaxoSmithkline, France), thiomersal (West Yorkshire, England), Phospholipon 90H (Natterman, K觟ln, Germany). Goat fat was obtained from a batch processed in our laboratory.
2.2.Extraction of goat fat and physicochemical characterization
Goat fat was extracted from the adipose tissue of Capra hircus by wet rendering achieved by subjecting the adipose tissue to moist heat by boiling with half its weight of water for 45 min. The molten fat was separated from aqueous phase after solidification. The extracted lipid was deodorized and decolorized to a white mass as earlier reported [9] and the following physicochemical properties determined using standard procedure [10] : melting point, refractive index, saponification value, unsaponifiable matter, acetyl value, iodine value and peroxide value.
Preparation of bulk lipid matrix
The bulk lipid matrix consisting of 30% w/w phospholipid in goat fat was prepared by fusion.
Preparation of unloaded and drug-loaded solid lipid microspheres
The unloaded and drug-loaded solid lipid microspheres were formulated by melt-homogenization technique [11] using Ultra-Turrax (T25 Basic, Ika Staufen, Germany) at 5 000 rpm for 10 min. In the case of drug containing microspheres, the drug was first mixed with the molten lipid matrix as it is stable in this lipid at that temperature. The quantities used are stated in Table 1 .
Evaluation of the formulated solid lipid microspheres
Determination of pH
The pH of the different batches of the unloaded and drugloaded solid lipid microsphere formulations (unlyophilized dispersions) were measured using a pH meter (Digital pH Meter, Labtech) at different time intervals. Triplicate determinations were done.
Determination of particle size and morphological characterization of solid lipid microspheres
The particle size of the surface-modified lipid microspheres was determined by computerized image analysis [11] on a photomicroscope (Lieca, Germany). With the aid of the software in the microscope, the projected perimeter diameters of the particles corresponding to the particle sizes of the lipid microspheres were determined and average calculated. The particle morphologies were also observed and photomicrographs taken. All these were done in time dependent manner.
Drug content analysis
A 5 mL volume of each of the drug-loaded solid lipid microspheres was centrifuged at 8 400 × g for 20 min to obtain aqueous and non-aqueous phases. A 20-fold dilution of the aqueous phase was prepared with methanol and the absorbance determined in a UV-Vis spectrophotometer (UNICO UV-2102 PC, USA) at a predetermined wavelength of 248 nm, and the encapsulation efficiency of the five drug-loaded formulations were calculated using Eqn. 1 [12] . The regression equation of Beer's plot for halofantrine in methanol was A = 2.448C (r 2 =0.977), where A is the absorbance of the solution and C is halofantrine concentration.
EE% = Actual amount
Theoretical amount 伊100 Eqn. 1
Preparation of biorelevant media for in vitro release studies
Simulated gastric fluid (SGF, pH 1.2) without pepsin, simulated intestinal fluid (SIF, pH 7.2) without pancreatin and phosphate buffer (pH 6.8) were prepared following standard procedures [13, 14] .
In vitro release studies
A Franz diffusion cell [15] was used for the studies. In each case, a finite volume of the optimized solid lipid microsphere formulation (H5) was placed in the donor compartment of the Franz diffusion cell separated from the receptor compartment by an artificial membrane (polycarbonate) (pore size 0.22 毺 m). The receptor compartment was filled with phosphate buffer pH 6.8, SGF (pH 1.2) or SIF (pH 7.2) and maintained at a temperature of (37依1) 曟 by means of a thermostatically controlled water bath, with agitation provided by a magnetic stirring bar at 50 rpm. Aliquot was removed and replaced by an equal volume of the receptor phase at different time interval up to 8 h and the samples collected analyzed for halofantrine content spectrophotometrically using a spectrophotometer (UNICO UV-2102 PC, USA). The drug content at each time point was calculated by reference to Beer's calibration in each biorelevent medium. The formulations (Halfan® 250 mg tablet and halofantrine-containing surface-modified solid lipid microspheres) were used for in vitro release studies [16] .
Data and statistical analysis
All experiments were performed in replicates (at least, n= 3) for validity of statistical analysis. Results were expressed as mean 依 SD. ANOVA and Student t-tests were performed on the data sets generated using Origin® for Windows, SPSS and SigmaPlot® 11. Differences were considered significant for P values < 0.05. Figures 1 and 2 show the particle size distribution of the unloaded and drug loaded lipid microspheres respectively. It was from Figure 1 that solid lipid microspheres with the least particle size (Batch U5) was selected for the formulation of drug loaded solid lipid microspheres. H1 to H5 represent solid lipid microspheres containing 1%, 2%, 3%, 4% and 5% w/w of halofantrine, respectively.
Results
Particle size analysis
pH analysis
The pH stability profiles for unloaded solid lipid microspheres containing respectively, 0.0%, 0.3%, 0.6%, 1.0%, and 1.5% w/w of polysorbate 80 (batches U1 to U5) and the halofantrine-loaded solid lipid microspheres (batches H1 to H5) are presented in Figures 3 and 4 H1 to H5 represent microspheres containing 1%, 2%, 3%, 4% and 5% w/w of halofantrine, respectively. Figure 6 . Photomicrographs of the drug containing lipid microspheres after 1 month of formulation. A=1.5% w/w polysorbate (80依1)% w/w halotantrine; B=1.5% w/ w polysorbate (80依2)% w/w halofamtrine; C=3% w/w halofantrine; D=1.5% w/w polysorbate (80依4)% w/w halotantrine; and E=1.5% w/w polysorbate (80依5)% w/w halotantrine. Bartepresents 50 毺 m.
Particle morphology
Encapsulation efficiency (EE%)
The encapsulation efficiencies of the solid lipid microspheres are presented in Figure 7 . Figure 8 shows in vitro release of halofantrine for both the formulated lipid microspheres (Batch H5) and that of the dispersed Halfan® tablet in SGF, SIF and PB (phosphate buffer). 
In vitro drug release
Discussion
Particle size analysis shows that increase in concentration of polysorbate 80 resulted in decrease in particle size at constant homogenization condition. This is consistent with earlier findings [17] . On storage, there were minor increases in the particle size after 3 months indicating high particle size stability, although, the particle sizes were low after formulation. The particle sizes were between (18.6依2.1) 毺 m to (29.3依2.9) 毺 m for the unloaded solid lipid microspheres after 3 months and (35.9依1.4) 毺 m to (20.9依1.1) 毺 m for the drug loaded lipid microspheres. It was also observed that there was increase in particle size on drug loading, which also increased as the drug content increased. This indicated that the drug was located mostly in the solid core of the microsphere since it is highly lipophilic. Particle size, particle size distribution and stability are a major issue considered by formulation scientists when formulating dispersed systems [18, 19] .
The pH stability profiles show that the pH of the unloaded solid lipid microspheres significantly changed (P<0.05) after storage. The pH profile of the drug-loaded solid lipid microspheres of the different batches showed the pH values were fairly constant between 24 h and 1 month presenting values of 6.1依1.2 to 6.9依1.6 and 6.1依3.1 to 7.3 依2.1 respectively. The pH values were affected by drug loading as there was a significant difference (P<0.05) between the pH values of the unloaded and drug loaded solid lipid microspheres. One has to be aware that since this formulation is particulate in nature and is dispersed in aqueous medium, particle surface pH in some systems may be 2 to 3 units different from the pH of the bulk because of double layer forces of attraction/adsorption of other ions in the continuous phase [20] .
The photomicrographs of the solid lipid microspheres revealed that they are crystalline in nature, spherical and uniform with a smooth surface. The particles appeared to be aggregate in nature without evidence of any collapsed particles. It should be noted that the micrograph presents the particles in two dimensions and particles viewed edgeon may not appear spherical.
The encapsulation efficiencies of the solid lipid microspheres indicated very high EE%. It can be inferred that the encapsulation efficiency increased with the increasing concentration of drug loaded into the lipid microspheres and also with duration of time. The significant increase (P<0.05) in the EE% with time indicates that after preparation, the lipid microspheres remained fluid. Analysis of the drug content within 24 h would be erroneous since complete crystallization had not occurred. Migration of drug from the aqueous phase into the lipid microspheres continued until complete crystallization had reached because the drug is highly lipophilic. The percentage of drug entrapped is also dependent upon the physicochemical properties of the drug, the nature of the lipid components selected, the solvent and the manner in which the components were combined.
In the in vitro release studies of halofantrine for both the formulated lipid microspheres (Batch H5) and that of the dispersed Halfan® tablet in SGF, SIF and PB (phosphate buffer), it was observed that halofantrine release was greater from the lipid microspheres than from the tablet formulation (crushed) at the end of the release period. This was as a result of solubility enhancement by the phospholipid-containing solid lipid microsphere. Phospholipid formulations not only enhance bioavailability of drugs with low aqueous solubility or low membrane penetration potential, but also improve or alter uptake and release of drugs [2, 21, 22] . The release profile revealed that the formulations tested in different biorelevant media had different maximum release. The novel formulation containing 5% w/w halofantrine released maximally after 7 h in phosphate buffer (pH 6.8) , while the commercial dosage form could only achieve about 30% maximum release in same media after 7 h. There was also a controlled release of halofantrine from the novel lipid microsphere formulation compared with the commercial dosage form. There was no burst release from the novel lipid microsphere dosage form. Release followed this order: PB > SIF > SGF. The decreased release rate of halofantrine from the tablet may be attributed to the granular nature of Halfan tablet and it has to dissolve before releasing the drug and also the solubility of the drug in the release media. Release studies were conducted in different biorelevant media to ascertain the possible behaviour of the formulation as it transits the entire gastrointestinal system since the formulation is intended for oral administration.
The solid lipid microspheres containing halofantrine exhibited an excellent release profile compared with the commercial table dosage form (Halfan®). This was as a result of the increase in solubility of the lipophilic drug. It is envisaged that there would be controlled release of halofantrine in vivo from this novel dosage form and this will ultimately enhance boavailability and a better therapeutic effect will be obtained. It is recommended that further research into use of a lipid matrix and phospholipid in the formulation of halofantrine be embarked upon.
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